Skip to content
Search

Latest Stories

Submit Guest Post

Indian Govt Approves Merger Of Vijaya, Dena Bank With Bank Of Baroda

Indian cabinet on Wednesday (2) approved the scheme of amalgamation for amalgamating Bank of Baroda, Vijaya Bank, and Dena Bank, with Bank of Baroda as the transferee bank and Vijaya Bank and Dena Bank as transferor banks.

The amalgamation will be the first-ever three-way consolidation of banks in India, with the amalgamated bank being India's second largest public sector bank.


The scheme will come into force on April 1, 2019.

The transferee bank shall issue shares to the shareholders of transferor banks as per share exchange ratio. Shareholders of the transferee bank and transferor banks shall be entitled to raise their grievances, if any, in relation to the share exchange ratio, through an expert committee.

The amalgamated banks will have access to a wider talent pool, and a large database that may be leveraged through analytics for competitive advantage in a rapidly digitalising banking context. Benefits would also flow as a result of wider reach and distribution network and reduction in distribution costs for the products and services through subsidiaries.

The amalgamation will help create a strong globally competitive bank with economies of scale and enable the realisation of wide-ranging synergies.

Meanwhile, the board of directors of the Bank of Baroda approved the swap ratio for the amalgamation. Accordingly, Vijaya Bank shareholders will get 402 shares of Bank of Baroda for 1,000 shares held of Vijaya Bank. Dena Bank shareholders will obtain 110 shares of Bank of Baroda for every 1,000 shares.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less